Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations

on behalf of the MTN-003 Protocol Team

Research output: Contribution to journalArticle

Abstract

Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) prevented HIV acquisition among men and women in several trials and is broadly recommended. In the VOICE and FEM-PrEP trials, however, TDF/FTC-based PrEP did not prevent HIV acquisition among women in eastern and southern Africa. Tenofovir was detected in plasma, reflecting exposure and adherence in recent days, in fewer than one-third of participants. Drug concentrations in hair, which represent cumulative exposure and adherence over weeks to months, have never previously been examined among women on PrEP. We compared tenofovir hair concentrations among women assigned to oral TDF/FTC in the VOICE trial to those among men and transgender women enrolled in 2 open-label PrEP studies, the iPrEx open-label extension (OLE) study and the U.S. PrEP Demonstration Project (PrEP Demo). Tenofovir hair concentrations were detectable in 55% of person-visits in VOICE, 75% of person-visits in iPrEx OLE (p = .006), and 98% of person-visits in PrEP Demo (p < .001). Median tenofovir hair concentrations corresponded to an estimated 0.2, 2.9, and 6.0 TDF/FTC doses taken per week in the three studies, respectively. In VOICE, combining tenofovir concentration data from plasma and hair suggested inconsistent, low-level product use. Incorporation of both short- and long-term adherence measures may allow for an improved understanding of patterns of drug-taking among women during global PrEP roll-out.

Original languageEnglish (US)
Pages (from-to)778-783
Number of pages6
JournalAIDS Research and Human Retroviruses
Volume33
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Tenofovir
Hair
HIV
Transgender Persons
Pre-Exposure Prophylaxis
Southern Africa
Eastern Africa

Keywords

  • adherence monitoring
  • hair concentrations
  • HIV and women
  • HIV prevention
  • plasma concentrations
  • pre-exposure prophylaxis

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. / on behalf of the MTN-003 Protocol Team.

In: AIDS Research and Human Retroviruses, Vol. 33, No. 8, 01.08.2017, p. 778-783.

Research output: Contribution to journalArticle

@article{c097d3228170450ebebee42fd4e0143b,
title = "Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations",
abstract = "Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) prevented HIV acquisition among men and women in several trials and is broadly recommended. In the VOICE and FEM-PrEP trials, however, TDF/FTC-based PrEP did not prevent HIV acquisition among women in eastern and southern Africa. Tenofovir was detected in plasma, reflecting exposure and adherence in recent days, in fewer than one-third of participants. Drug concentrations in hair, which represent cumulative exposure and adherence over weeks to months, have never previously been examined among women on PrEP. We compared tenofovir hair concentrations among women assigned to oral TDF/FTC in the VOICE trial to those among men and transgender women enrolled in 2 open-label PrEP studies, the iPrEx open-label extension (OLE) study and the U.S. PrEP Demonstration Project (PrEP Demo). Tenofovir hair concentrations were detectable in 55{\%} of person-visits in VOICE, 75{\%} of person-visits in iPrEx OLE (p = .006), and 98{\%} of person-visits in PrEP Demo (p < .001). Median tenofovir hair concentrations corresponded to an estimated 0.2, 2.9, and 6.0 TDF/FTC doses taken per week in the three studies, respectively. In VOICE, combining tenofovir concentration data from plasma and hair suggested inconsistent, low-level product use. Incorporation of both short- and long-term adherence measures may allow for an improved understanding of patterns of drug-taking among women during global PrEP roll-out.",
keywords = "adherence monitoring, hair concentrations, HIV and women, HIV prevention, plasma concentrations, pre-exposure prophylaxis",
author = "{on behalf of the MTN-003 Protocol Team} and Koss, {Catherine A.} and Peter Bacchetti and Hillier, {Sharon L.} and Edward Livant and Howard Horng and Nyaradzo Mgodi and Mirembe, {Brenda G.} and Feliciano, {Kailazarid Gomez} and Stephanie Horn and Liu, {Albert Y.} and Glidden, {David V.} and Grant, {Robert M.} and Benet, {Leslie Z.} and Alexander Louie and {Van Der Straten}, Ariane and Chirenje, {Z. Mike} and Marrazzo, {Jeanne M.} and Monica Gandhi and Shayhana Ganesh and Sharika Gappoo and Marwah Jenneker and Shahnaaz Kadwa and Vilma Naicker and Sarita Naidoo and Gita Ramjee and Yuki Sookrajh and Linda Zako and Tsitsi Magure and Felix Mhlanga and Kathy Mngadi and Gonasagrie Nair and Clemensia Nakabiito and Thesla Palanee and Baningi Mkhize and Nomampondo Barnabas and Gondwe, {Daniel K.} and Oupa Mafumane and Teopista Nakyanzi and Roberta Black and Usha Sharma and Scharla Estep and Soto-Torres, {Lydia E.} and Forsyth, {Andrew D.} and Jim Turpin and Jeanna Piper and Heather Watts and Gabelnick, {Henry L.} and James Rooney and Katherine Bunge and Craig Hendrix",
year = "2017",
month = "8",
day = "1",
doi = "10.1089/aid.2016.0202",
language = "English (US)",
volume = "33",
pages = "778--783",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations

AU - on behalf of the MTN-003 Protocol Team

AU - Koss, Catherine A.

AU - Bacchetti, Peter

AU - Hillier, Sharon L.

AU - Livant, Edward

AU - Horng, Howard

AU - Mgodi, Nyaradzo

AU - Mirembe, Brenda G.

AU - Feliciano, Kailazarid Gomez

AU - Horn, Stephanie

AU - Liu, Albert Y.

AU - Glidden, David V.

AU - Grant, Robert M.

AU - Benet, Leslie Z.

AU - Louie, Alexander

AU - Van Der Straten, Ariane

AU - Chirenje, Z. Mike

AU - Marrazzo, Jeanne M.

AU - Gandhi, Monica

AU - Ganesh, Shayhana

AU - Gappoo, Sharika

AU - Jenneker, Marwah

AU - Kadwa, Shahnaaz

AU - Naicker, Vilma

AU - Naidoo, Sarita

AU - Ramjee, Gita

AU - Sookrajh, Yuki

AU - Zako, Linda

AU - Magure, Tsitsi

AU - Mhlanga, Felix

AU - Mngadi, Kathy

AU - Nair, Gonasagrie

AU - Nakabiito, Clemensia

AU - Palanee, Thesla

AU - Mkhize, Baningi

AU - Barnabas, Nomampondo

AU - Gondwe, Daniel K.

AU - Mafumane, Oupa

AU - Nakyanzi, Teopista

AU - Black, Roberta

AU - Sharma, Usha

AU - Estep, Scharla

AU - Soto-Torres, Lydia E.

AU - Forsyth, Andrew D.

AU - Turpin, Jim

AU - Piper, Jeanna

AU - Watts, Heather

AU - Gabelnick, Henry L.

AU - Rooney, James

AU - Bunge, Katherine

AU - Hendrix, Craig

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) prevented HIV acquisition among men and women in several trials and is broadly recommended. In the VOICE and FEM-PrEP trials, however, TDF/FTC-based PrEP did not prevent HIV acquisition among women in eastern and southern Africa. Tenofovir was detected in plasma, reflecting exposure and adherence in recent days, in fewer than one-third of participants. Drug concentrations in hair, which represent cumulative exposure and adherence over weeks to months, have never previously been examined among women on PrEP. We compared tenofovir hair concentrations among women assigned to oral TDF/FTC in the VOICE trial to those among men and transgender women enrolled in 2 open-label PrEP studies, the iPrEx open-label extension (OLE) study and the U.S. PrEP Demonstration Project (PrEP Demo). Tenofovir hair concentrations were detectable in 55% of person-visits in VOICE, 75% of person-visits in iPrEx OLE (p = .006), and 98% of person-visits in PrEP Demo (p < .001). Median tenofovir hair concentrations corresponded to an estimated 0.2, 2.9, and 6.0 TDF/FTC doses taken per week in the three studies, respectively. In VOICE, combining tenofovir concentration data from plasma and hair suggested inconsistent, low-level product use. Incorporation of both short- and long-term adherence measures may allow for an improved understanding of patterns of drug-taking among women during global PrEP roll-out.

AB - Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) prevented HIV acquisition among men and women in several trials and is broadly recommended. In the VOICE and FEM-PrEP trials, however, TDF/FTC-based PrEP did not prevent HIV acquisition among women in eastern and southern Africa. Tenofovir was detected in plasma, reflecting exposure and adherence in recent days, in fewer than one-third of participants. Drug concentrations in hair, which represent cumulative exposure and adherence over weeks to months, have never previously been examined among women on PrEP. We compared tenofovir hair concentrations among women assigned to oral TDF/FTC in the VOICE trial to those among men and transgender women enrolled in 2 open-label PrEP studies, the iPrEx open-label extension (OLE) study and the U.S. PrEP Demonstration Project (PrEP Demo). Tenofovir hair concentrations were detectable in 55% of person-visits in VOICE, 75% of person-visits in iPrEx OLE (p = .006), and 98% of person-visits in PrEP Demo (p < .001). Median tenofovir hair concentrations corresponded to an estimated 0.2, 2.9, and 6.0 TDF/FTC doses taken per week in the three studies, respectively. In VOICE, combining tenofovir concentration data from plasma and hair suggested inconsistent, low-level product use. Incorporation of both short- and long-term adherence measures may allow for an improved understanding of patterns of drug-taking among women during global PrEP roll-out.

KW - adherence monitoring

KW - hair concentrations

KW - HIV and women

KW - HIV prevention

KW - plasma concentrations

KW - pre-exposure prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=85026883112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026883112&partnerID=8YFLogxK

U2 - 10.1089/aid.2016.0202

DO - 10.1089/aid.2016.0202

M3 - Article

C2 - 28253024

AN - SCOPUS:85026883112

VL - 33

SP - 778

EP - 783

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 8

ER -